With more than 5 million fatalities and close to 300 million reported cases, COVID-19 is the
first documented pandemic due to a coronavirus that continues to be a major health …

Since the start of the coronavirus disease 2019 (COVID‐19) pandemic, new variants of
severe acute respiratory syndrome coronavirus 2 (SARS‑CoV‑2) have emerged …

With the emergence of multiple predominant SARS-CoV-2 variants, it becomes important to
have a comprehensive assessment of their viral fitness and transmissibility. Here, we …

Remdesivir 1 is an phosphoramidate prodrug that releases the monophosphate of
nucleoside GS-441524 (2) into lung cells, thereby forming the bioactive triphosphate 2-NTP …

The rapid spread and strong immune evasion of the SARS-CoV-2 Omicron subvariants has
raised serious concerns for the global COVID-19 pandemic. These new variants exhibit …

SARS-CoV-2 and its variants, especially the Omicron variant, remain a great threat to human
health. The need to discover potent compounds that may control the SARS-CoV-2 virus …

Ongoing emergence of SARS-CoV-2 Omicron subvariants and their rapid worldwide spread
pose a threat to public health. From November 2022 to February 2023, newly emerged …

Background Remdesivir is approved for treatment of coronavirus disease 2019 (COVID-19)
in nonhospitalized and hospitalized adult and pediatric patients. Here we present severe …

Since the outbreak of the COVID-19 pandemic, severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2) RNA-dependent RNA polymerase (RdRp) has become a main …

In vitro selection of remdesivir-resistant severe acute respiratory syndrome coronavirus 2
(SARS-CoV-2) revealed the emergence of a V166L substitution, located outside of the …